US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

79.83

-0.2600-0.32%

Volume:99.45K

Turnover:7.91M

Market Cap:944.91M

PE:-22.62

High:80.20

Open:79.67

Low:78.37

Close:80.09

52wk High:114.69

52wk Low:17.31

Shares:11.84M

Float Shares:7.16M

Volume Ratio:0.51

T/O Rate:1.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.5291

EPS(LYR):-7.8322

ROE:-301.19%

ROA:-47.54%

PB:24.43

PE(LYR):-10.19

Loading ...

Overview Company News Filings

Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum

Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)

Analysts’ Top Healthcare Picks: Cogstate Ltd (COGZF), Palvella Therapeutics (PVLA)

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Palvella Therapeutics (PVLA)

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Progyny (PGNY)

Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright

Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating

Palvella Therapeutics management to meet virtually with Craig-Hallum

Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis

Palvella Therapeutics Inc : TD Cowen Raises Target Price to $190 From $133

THOMSON REUTERS

Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

Palvella Therapeutics (PVLA) Receives a Buy from BTIG

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)

Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics

BUY Rating on Palvella Therapeutics: De-Risked SELVA Phase 3 Design Positions QTORIN Rapamycin for First-in-Class MLM Approval and Compelling Risk–Reward

BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook

Palvella Therapeutics issues update, 2026 outlook

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":79.83,"timestamp":1771443641947,"preClose":80.09,"halted":0,"volume":99453,"delay":0,"changeRate":-0.0032463478586590724,"floatShares":7158500,"shares":11836490,"eps":-3.529122,"marketStatus":"Trading","change":-0.26,"latestTime":"02-18 14:41:00 EST","open":79.67,"high":80.195,"low":78.37,"amount":7906422.00324,"amplitude":0.022787,"askPrice":79.97,"askSize":62,"bidPrice":79.51,"bidSize":208,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":80.09,"preHourTrading":{"tag":"盘前","latestPrice":79.8,"preClose":80.09,"latestTime":"09:19 EST","volume":85,"amount":6783,"timestamp":1771424378576,"change":-0.29,"changeRate":-0.003621,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":80.09,"preClose":80.09,"latestTime":"17:01 EST","volume":589,"amount":47173.29,"timestamp":1771365701500,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.505276,"impliedVol":2.2801,"impliedVolPercentile":0.992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":7158500,"roa":"-47.54%","roe":"-301.19%","lyrEps":-7.832217,"volumeRatio":0.505276,"shares":11836490,"dividePrice":0,"high":80.195,"amplitude":0.022787,"preClose":80.09,"low":78.37,"week52Low":17.31,"pbRate":"24.43","week52High":114.69,"institutionHeld":0,"latestPrice":79.83,"committee":0.540741,"eps":-3.529122,"divideRate":0,"volume":99453,"delay":0,"ttmEps":-3.529122,"open":79.67,"prevYearClose":104.67,"prevWeekClose":81.54,"prevMonthClose":76.69,"prevQuarterClose":104.67,"fiveDayClose":81.01,"twentyDayClose":98.01,"sixtyDayClose":96.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1768107600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-02-17","current":-22.69403,"percent":0.219931,"low":-39.17838,"twenty":-29.476878,"median":-17.026789,"eighty":20.066674,"high":46.119317,"avg":-10.326411,"sd":23.631822,"marketCap":965147394},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-17","current":-29.289494,"twenty":-29.476878,"median":-17.026789,"eighty":20.066674,"marketCap":965147394}],"updateTime":1771416053543},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612441405","title":"Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2612441405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612441405?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:25","pubTimestamp":1771424724,"startTime":"0","endTime":"0","summary":"In a report released today, Albert Lowe from Craig-Hallum reiterated a Buy rating on Palvella Therapeutics, with a price target of $205.00. Accordi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-gets-a-buy-from-craig-hallum-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-gets-a-buy-from-craig-hallum-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2611485641","title":"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611485641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611485641?lang=en_us&edition=fundamental","pubTime":"2026-02-16 21:01","pubTimestamp":1771246896,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and Palvella ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1868837300.USD","SGXZ99366536.SGD","IE00BJJMRX11.SGD","LU1551013342.USD","LU2168563687.JPY","LU2168564495.EUR","LU0787776722.HKD","LU2750360641.GBP","IE00B1XK9C88.USD","IE00BK4W5L77.USD","IE0002141913.USD","IE00B7KXQ091.USD","LU0198837287.USD","LU0943347566.SGD","IE0009355771.USD","LU2491050071.SGD","LU2756315318.SGD","SG9999015945.SGD","IE0004445239.USD","LU1868836591.USD","LU2471134952.CNY","LU0029874061.USD","LU0672654240.SGD","BK4588","IE00BFSS7M15.SGD","IE00BK4W5M84.HKD","LU1232071149.USD","LU0320765992.SGD","LU1804176565.USD","LU2168564065.EUR","LU2360106947.USD","LU1064131342.USD","LU1267930730.SGD","LU2471134879.HKD","BK4516","IE00BFTCPJ56.SGD","SG9999014898.SGD","LU1974910355.USD","LU0158827948.USD","LU0320765059.SGD","LU0061475181.USD","LU0466842654.USD","BK4585","LU0238689110.USD","LU2357305700.SGD","SG9999015978.USD","IE0005OL40V9.USD","IE00B775H168.HKD","SG9999014906.USD","LU2324357040.USD","LU1057294990.SGD","LU0823434583.USD","LU0432979614.USD","IE00B4JS1V06.HKD","LU2023250330.USD","IE00BFSS8Q28.SGD","LU0471298694.HKD","IE00BJLML261.HKD","LU2750360997.AUD","LU2461242641.AUD","LU0354030511.USD","LU2023250504.SGD","PVLA","SGXZ57979304.SGD","LU0786609619.USD","LU1035775433.USD","BK4112","BLSG","SG9999017495.SGD","LU0820561818.USD","SGXZ81514606.USD","LU0058720904.USD","ELIL","LU0964807845.USD","LU2468319806.SGD","LU2108987350.USD","BK4137","IE0004445015.USD","LU0683600562.USD","LU2491049909.HKD","LU2237438978.USD","LU1983299246.USD","LU0689472784.USD","LU2462157665.USD","LU2746668974.SGD","LU1988902786.USD","LLY","LU2023251221.USD","SGXZ31699556.SGD","IE00BJJMRZ35.SGD","LU2756315664.SGD","LU2063271972.USD","IE00B1BXHZ80.USD","IE00B4R5TH58.HKD","LU0323591593.USD","LU1917777945.USD","SGXZ51526630.SGD","LU0109394709.USD","LU1323610961.USD","XBI","LU1127390331.HKD","SG9999013999.USD","LU0079474960.USD","LU0471298777.SGD","LU1868836757.USD","LU0109391861.USD","BK4581","LU1145028129.USD","LU2089284900.SGD","LU2213496289.HKD","LU0289739699.SGD","LU0316494557.USD","LU0353189680.USD","LU2237443895.HKD","IE00B2B36J28.USD","SG9999018857.SGD","LU1291159041.SGD","LU1023059063.AUD","LU1868837136.USD","LU2211815571.USD","LU2602419157.SGD","LU2111349929.HKD","LU0417517546.SGD","LU0820561909.HKD","BK4534","LU0882574139.USD","BK4007","LU0096364046.USD","LU2237443382.USD","LU2168564222.USD","ELIS","LU1814569148.SGD","LU2087625088.SGD","LU2106854487.HKD","LU0256863811.USD","LU0385154629.USD","LU1069344957.HKD","BLSX","LU2491050154.USD","IE00BJT1NW94.SGD","LU2552382058.USD","LU0203202063.USD","LU0820562030.AUD","LU1061106388.HKD","LU0203201768.USD","LU2237443465.HKD","LU0122379950.USD","LU0823434740.USD","LU2361044865.SGD","LU2746668461.USD","SG9999018865.SGD","LU0225283273.USD","LU1720051108.HKD","LU2456880835.USD","LU1712237335.SGD","IE00BWXC8680.SGD","LU2896262040.SGD","LU0210536198.USD","LU2237443622.USD","LU2471134523.USD","LU2237443978.SGD","LU1720051017.SGD","IE00BN29S564.USD","LU2271345857.HKD","LU0823416689.USD","LU2237443549.SGD","LU2361044949.HKD","LU2236285917.USD","LU2471134796.USD","LU2264538146.SGD","LU0097036916.USD","LU0456855351.SGD","BK4533","SG9999014914.USD","LU2552382215.SGD","SG9999014880.SGD","LU0882574055.USD","SG9999001176.SGD","BK4139","LU0114720955.EUR","GB00BDT5M118.USD","LU0128526141.USD","LU1551013425.SGD","LU2112291526.USD","LU0889565916.HKD","LU2028103732.USD","SG9999015952.SGD","LU2265009873.SGD","LU0640476718.USD","IE00BKDWB100.SGD","LLYZ","LU2168564149.EUR","LU0106261372.USD","LU0708995401.HKD","SG9999015986.USD","LU1280957306.USD","LU1629891620.HKD","LABU","LU0006306889.USD","LU0353189763.USD","LU1623119135.USD","SG9999001176.USD","LU0094547139.USD","LU2089283258.USD","LU2417539215.USD","LU0266013472.USD","LU2552382132.HKD","IE00BJJMRY28.SGD","LU2361045086.USD","LU2089984988.USD","LU0256863902.USD","LLYX","LU1989771016.USD","LU1366192091.USD","LU1093756325.SGD","LU0158827781.USD","LU1093756168.USD","LU0234572021.USD","IE00BKPKM429.USD","LU0354030438.USD","BK4599","LU1548497426.USD","LU1868836914.USD"],"gpt_icon":0},{"id":"2611906033","title":"Analysts’ Top Healthcare Picks: Cogstate Ltd (COGZF), Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611906033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611906033?lang=en_us&edition=fundamental","pubTime":"2026-02-13 06:40","pubTimestamp":1770936008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogstate Ltd (COGZF – Research Report) and Palvella ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-cogstate-ltd-cogzf-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-cogstate-ltd-cogzf-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4137","XLV","COGZF","BK4167","LU0029874061.USD","BK4588","LABU","BK4139","BK4581","HCSG","XBI","BK4585","PVLA"],"gpt_icon":0},{"id":"2610652542","title":"Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610652542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610652542?lang=en_us&edition=fundamental","pubTime":"2026-02-10 00:10","pubTimestamp":1770653406,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and Palvell...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-krystal-biotech-krys-and-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-krystal-biotech-krys-and-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","XBI","BK4588","BK4585","LU0029874061.USD","XLV","BK4581","HCSG","LU0128526141.USD","KRYS","LABU","PVLA"],"gpt_icon":0},{"id":"2610565469","title":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Progyny (PGNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610565469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610565469?lang=en_us&edition=fundamental","pubTime":"2026-02-09 23:20","pubTimestamp":1770650410,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Palvella Therapeutics (PVLA – Research Report) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-progyny-pgny-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-progyny-pgny-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABU","HCSG","XLV","BK4581","LU0128526141.USD","PGNY","XBI","BK4585","LU0029874061.USD","PVLA","BK4137","BK4154","BK4588"],"gpt_icon":0},{"id":"2608874070","title":"Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874070?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:58","pubTimestamp":1770127087,"startTime":"0","endTime":"0","summary":"In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Palvella Therapeutics, with a price target of $200.00. Acco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2608892765","title":"Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2608892765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608892765?lang=en_us&edition=fundamental","pubTime":"2026-02-03 03:25","pubTimestamp":1770060354,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics and keeping the price target at $150.00. Sam Slutsky has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-pvla-mechanistic-validation-unmet-need-and-pivotal-trial-catalysts-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-pvla-mechanistic-validation-unmet-need-and-pivotal-trial-catalysts-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2608898432","title":"Palvella Therapeutics management to meet virtually with Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2608898432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608898432?lang=en_us&edition=fundamental","pubTime":"2026-02-02 23:15","pubTimestamp":1770045334,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on February 11 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-management-to-meet-virtually-with-craig-hallum-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-management-to-meet-virtually-with-craig-hallum-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2608869868","title":"Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869868","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869868?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:30","pubTimestamp":1770035425,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc., a clinical-stage biopharmaceutical company focused on rare skin diseases, announced the publication of a systematic review in Clinical and Experimental Dermatology synthesizing clinical evidence on off-label cutaneous statin use for porokeratosis. The review, which includes 24 studies, highlights persistent treatment gaps due to the lack of FDA-approved therapies for this condition and supports the development of Palvella's QTORIN pitavastatin for disseminated superficial actinic porokeratosis . The company indicated that QTORIN pitavastatin is anticipated to enter Phase 2 clinical development in the second half of 2026. No new clinical study results have been presented; future trials are planned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL7TLvX2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","LU2095319765.USD","PVLA","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","BK4139","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4585"],"gpt_icon":0},{"id":"2608868869","title":"Palvella Therapeutics Inc : TD Cowen Raises Target Price to $190 From $133","url":"https://stock-news.laohu8.com/highlight/detail?id=2608868869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608868869?lang=en_us&edition=fundamental","pubTime":"2026-02-02 18:47","pubTimestamp":1770029252,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2607040536","title":"Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040536?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:10","pubTimestamp":1769789418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR – Research Report), Palvella Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-danaher-dhr-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-danaher-dhr-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU2112291526.USD","LU0689472784.USD","BK4533","LU1923622614.USD","LU1791710582.SGD","LU0320765059.SGD","LU1023059063.AUD","LU0882574055.USD","LU0511384066.AUD","LU2125909593.SGD","BK4581","LU1791710400.SGD","LU2023250504.SGD","LU0390134368.USD","XLV","LU2265009873.SGD","LU0528227936.USD","LU1551013342.USD","LU1804176565.USD","SG9999013999.USD","LU0672654240.SGD","SGXZ23171101.USD","LU1917777945.USD","BK4139","LU2106854487.HKD","PVLA","LU0114720955.EUR","LU1267930730.SGD","BK4504","LU1057294990.SGD","LU0432979614.USD","LU0312595415.SGD","BK4121","LU0157215616.USD","LU0289739343.SGD","LU2125909247.SGD","LU0289961442.SGD","LU1061106388.HKD","IE00BQXX3D17.EUR","DHR","HCSG","XBI","LU0820561909.HKD","BK4137","LU0820561818.USD","LU0097036916.USD","LU0708995401.HKD","LU0109391861.USD","LABU"],"gpt_icon":0},{"id":"2607082134","title":"Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607082134?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:43","pubTimestamp":1769690580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 07:43 ET (12:43 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2607084233","title":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084233?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:20","pubTimestamp":1769689217,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Nuri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-nurix-therapeutics-nrix-and-jazz-pharmaceuticals-jazz-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-nurix-therapeutics-nrix-and-jazz-pharmaceuticals-jazz-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823416689.USD","JAZZ","BK4581","LABU","BK4532","BK4585","IE00BN0W2W23.USD","LU0320765992.SGD","NRIX","BK4139","IE00BN0W2V16.EUR","PVLA","LU0154245673.USD","BK4588","BK4007","LU0109394709.USD","LU0889565916.HKD","XLV","BK4533","LU0029874061.USD","BK4137","HCSG","LU0128526141.USD","XBI","IE00BN0W2T93.GBP","LU0154245756.USD"],"gpt_icon":0},{"id":"2605143659","title":"Palvella Therapeutics (PVLA) Receives a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2605143659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605143659?lang=en_us&edition=fundamental","pubTime":"2026-01-21 02:06","pubTimestamp":1768932390,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee maintained a Buy rating on Palvella Therapeutics on January 16 and set a price target of $192.00. According to TipRanks...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2604918205","title":"Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604918205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604918205?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:36","pubTimestamp":1768584960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 12:36 ET (17:36 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2603967369","title":"Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603967369?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:20","pubTimestamp":1768569611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Nuri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","LU0029874061.USD","BK4588","NRIX","BK4137","BK4581","LABU","BK4112","LU0128526141.USD","BK4585","BK4139","XBI"],"gpt_icon":0},{"id":"2603616576","title":"Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616576?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:57","pubTimestamp":1768395440,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of $150.00. Sam Slutsky has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/physician-survey-underscores-undervalued-commercial-upside-for-qtorin-topical-rapamycin-supporting-buy-on-palvella-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/physician-survey-underscores-undervalued-commercial-upside-for-qtorin-topical-rapamycin-supporting-buy-on-palvella-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2602306450","title":"BUY Rating on Palvella Therapeutics: De-Risked SELVA Phase 3 Design Positions QTORIN Rapamycin for First-in-Class MLM Approval and Compelling Risk–Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2602306450","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602306450?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:45","pubTimestamp":1767987944,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital mainta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-palvella-therapeutics-de-risked-selva-phase-3-design-positions-qtorin-rapamycin-for-first-in-class-mlm-approval-and-compelling-risk-reward-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-palvella-therapeutics-de-risked-selva-phase-3-design-positions-qtorin-rapamycin-for-first-in-class-mlm-approval-and-compelling-risk-reward-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BUY","MLM"],"gpt_icon":0},{"id":"2602375197","title":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375197?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:55","pubTimestamp":1767963328,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2602375851","title":"Palvella Therapeutics issues update, 2026 outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375851?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:36","pubTimestamp":1767962162,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) provided a corporate update and 2026 strategic outlook on the Company’s late clinical-stage pipeline and QTORIN platfo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-issues-update-2026-outlook-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-issues-update-2026-outlook-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":123,"code":"91000000","status":"200"}]}}